It has been established through clinical trials that GLP-1 receptor agonists (liraglutide and semaglutide) have proven to be consistently useful in lowering body weight, enhancing glycaemic control, and reducing cardiovascular risk [7,8,9].Nevertheless, since GLP-1 receptor agonists have the capability to work on several central nervous pathways, including the one controlling appetite, reward circuits, and the pancreatic-enteric-brain axis, the potential psychological impact of such agonists has increased with time [10,11,12]
Wegovy reduces appetite, which can lead to irregular eating
Rev Med Chil 2018;146:1444-51
Metabolic improvements extended to cardiovascular risk factors, with significant reductions in systolic blood pressure (mean decrease of 9.88 mm Hg) and diastolic blood pressure (mean decrease of 3.88 mm Hg)
How PlexusDx Supports a More Personalized Approach PlexusDx partners exclusively with licensed 503A compounding pharmacies that employ rigorous stability testing and cold-chain protocols
A receptor agonist is a type of medication that mimics a natural hormone in your body